G Bolli, F Dotta, E Rochotte, SE Cohen - Diabetes Obes Metab, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 49 - Related articles - All 2 versions
P Ltd, UK Sandwich - International journal of clinical practice - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 19 - Related articles - BL Direct - All 4 versions
GT McMahon, RA Arky - N Engl J Med, 2007 - scielo.oces.mctes.pt Resumo A propósito de um doente com diabetes mellitus (DM) tipo 2, com controlo
glicémico insuficiente com agen- tes orais, é feita uma recomendação
terapêutica baseada na discussão clínica e no mecanismo de benefício de ... Cited by 27 - Related articles - View as HTML - BL Direct - All 14 versions
M Hegewald, RO Crapo, RL Jensen - Diabetes Technology & Therapeutics, 2007 - liebertonline.com The need for frequent insulin injections to achieve optimal glycemic control
remains a major barrier to initiating and maintaining insulin therapy in
diabetes. The inhaled route of insulin ad- ministration offers many ... Cited by 9 - Related articles - BL Direct - All 3 versions
M Monami, N Marchionni, E Mannucci - Diabetes Research and Clinical Practice, 2008 - Elsevier The treatment with rosiglitazone could be associated with increased risk for
myocardial infarction (MI). This meta-analysis is aimed at identifying
moderators of the effect of rosiglitazone on the risk of MI and chronic ... Cited by 7 - Related articles - All 18 versions
- ►diabetesjournals.org J Rosenstock, WT Cefalu, PA Hollander, A … - Diabetes care, 2008 - Am Diabetes Assoc RESULTS—Small differences in FEV 1 favoring subcutaneous insulin developed
during the first 3 months but did not progress. Adjusted treatment group
differences in FEV 1 annual rate of change were −0.007 l/year (90% CI ... Cited by 6 - Related articles - All 10 versions
G Dailey - Clinical therapeutics, 2007 - Elsevier Results: Eight clinical studies to date have reported that IDPI consistently
improved glycemic control, whether used in combination with longer-acting SC
insulin regimens in patients with type 1 or type 2 DM or to supplement or ... Cited by 6 - Related articles - All 3 versions
AH Barnett, S Bellary - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin
administered by oral inhalation before meals. It provides a non-invasive
alternative to multiple subcutaneous injections for the treatment of ... Cited by 5 - Related articles - BL Direct - All 6 versions
- ►atsjournals.org MB Drummond, PF Schwartz, WT Duggan, JG … - American Journal of Respiratory and Critical Care …, 2008 - Am Thoracic Soc Measurements and Main Results: The mean intersession absolute change in DL CO
using the highly standardized method was 1.45 ml/minute/mm Hg (5.64%) compared
with 2.49 ml/minute/mm Hg (9.52%) in the routine testing group (P < 0.0001 ... Cited by 5 - Related articles - All 5 versions
AH Stonehouse, DG Maggs - Current Drug Therapy, 2007 - ingentaconnect.com Abstract: Type 2 diabetes results from progressive -cell dysfunction and insulin
resistance, leading to progressive wors- ening of glycemic control, and
increased risk of microvascular and macrovascular complications. ... Cited by 6 - Related articles - BL Direct
